Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Confined copper depletion via a hydrogel platform for reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant colorectal cancer.

Journal of controlled release : official journal of the Controlled Release Society - 1 Nov 2024

Wang Jue, Sun Xiangshi, Zhao Zhiwen, Wang Guanru, Wang Dangge, Li Yaping

Abstract excerpt

BRAFV600E-mutant colorectal cancer (CRC) is resistant to most first-line therapeutics, including the BRAF inhibitor dabrafenib and epidermal growth factor receptor (EGFR) inhibitor cetuximab. Although copper depletion shows promise in reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant CRC, its application is limited by the potential for excessive copper depletion in non-tumor objects. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Copper

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogels

Share to Imidazoles

Share to Mice, Nude

Share to Nanoparticles

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 39306044
DOI: 10.1016/j.jconrel.2024.09.034

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Confined copper depletion via a hydrogel platform for reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant colorectal cancer.PMID 39306044Read ↗

Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132‐Loaded Fe‐MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal CancerSemantic proximity Read ↗

Nanoparticle-based drug delivery systems: What can they really do in vivo?Semantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity.Semantic proximity Read ↗

One Stone, Two Birds: A Peptide‐Au(I) Infinite Coordination Supermolecule for the Confederate Physical and Biological Radiosensitization in Cancer Radiation TherapySemantic proximity Read ↗

Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanoma via pyroptosis.Semantic proximity Read ↗

Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.Semantic proximity Read ↗

Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.Semantic proximity Read ↗

A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.Semantic proximity Read ↗

Resiquimod-encapsulated MOF525 for Sustained Immunostimulant Release and Synergistic Photodynamic– Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Tumor Microenvironment-Responsive CA@ZIF-8/MnO 2 Nanoreactor for Self-Reinforcing Cascade Chemodynamic Therapy and ImmunomodulationSemantic proximity Read ↗

The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodelingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.